Study guide
6.3 Infectious Diseases and Antimicrobial Stewardship
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
6.3 Infectious Diseases and Antimicrobial Stewardship
Key Takeaways Explain This Topic AI
Antimicrobial stewardship balances PK/PD targets: time-dependent beta-lactams require optimized time above MIC (T > MIC), aminoglycosides require peak concentration (Cmax/MIC), and vancomycin/fluoroquinolones require total drug exposure (AUC/MIC).
Outpatient CAP treatment stratifies healthy adults (high-dose amoxicillin or doxycycline) versus those with chronic comorbidities (beta-lactam + macrolide/doxycycline OR respiratory fluoroquinolone).
Uncomplicated female cystitis is treated with nitrofurantoin (5 days), fosfomycin (single dose), or TMP-SMX (3 days); asymptomatic bacteriuria must only be treated in pregnancy or before invasive urologic procedures.
Clostridioides difficile infection is treated first-line with oral vancomycin (125 mg QID x 10 days) or fidaxomicin (200 mg BID x 10 days); metronidazole is no longer recommended for initial episodes.
True cross-reactivity between penicillins and 3rd/4th generation cephalosporins or carbapenems is < 1-2% due to dissimilar R1 side chains, allowing safe use unless history indicates severe IgE-mediated anaphylaxis with identical side-chain structures.
Last updated: August 2026
Antimicrobial Stewardship and Pharmacodynamics
Antimicrobial Stewardship Programs (ASPs) optimize clinical outcomes, minimize toxicities, and reduce the selective pressure driving antimicrobial resistance. Key ASP interventions include prospective audit and feedback, formulary restriction, automatic IV-to-oral step-down protocols, dose optimization based on pharmacokinetic/pharmacodynamic (PK/PD) indices, and de-escalation based on microbiological culture and susceptibility testing.
PK/PD Classifications of Antimicrobials +-------------------------------------------------------------------------+
- | ANTIMICROBIAL PK/PD CLASSIFICATION |
- +-------------------------------------------------------------------------+
- | |
- | 1. TIME-DEPENDENT (T > MIC) |
- | - Goal: Maximize time serum concentration exceeds MIC (%T > MIC) |
- | - Strategy: Frequent intermittent dosing, extended or continuous IV |
- | - Drug Classes: Penicillins, Cephalosporins, Carbapenems, Aztreonam|
- | |
- | 2. CONCENTRATION-DEPENDENT (Cmax / MIC) |
- | - Goal: Maximize peak serum concentration relative to MIC |
- | - Strategy: High-dose, extended-interval (once-daily) dosing |
- | - Drug Classes: Aminoglycosides (Gentamicin, Tobramycin), Daptomycin|
- | |
- | 3. EXPOSURE-DEPENDENT (AUC / MIC) |
- | - Goal: Maximize 24-hour total drug exposure relative to MIC |
- | - Strategy: Optimize total daily dose (AUC24 / MIC ratio) |
- | - Drug Classes: Vancomycin (target AUC 400-600), Fluoroquinolones, |
- | Macrolides, Tetracyclines |
- +-------------------------------------------------------------------------+
- Community-Acquired Respiratory Infections
- Community-Acquired Pneumonia (CAP)
Primary pathogens include Streptococcus pneumoniae , Haemophilus influenzae , Moraxella catarrhalis , and atypical organisms ( Mycoplasma pneumoniae , Chlamydia pneumoniae , Legionella pneumophila ).
Clinical Setting & Patient Profile Recommended Empiric Regimen Rationale & Clinical Comments
Outpatient: Healthy, No Comorbidities High-Dose Amoxicillin ( 1 g 1\text{ g} 1 g PO TID) OR Doxycycline ( 100 mg 100\text{ mg} 100 mg PO BID) Amoxicillin overcomes intermediate penicillin-resistant S. pneumoniae ; macrolide monotherapy (azithromycin) is only acceptable if local pneumococcal resistance < 25 % < 25\% < 25%
Outpatient: With Comorbidities (COPD, heart failure, DM, CKD, alcoholism) Combination: Beta-lactam ( Amoxicillin/clavulanate 875 / 125 mg 875/125\text{ mg} 875/125 mg PO BID or Cefuroxime axetil 500 mg 500\text{ mg} 500 mg BID) PLUS Macrolide ( Azithromycin ) or Doxycycline ; OR Monotherapy: Respiratory Fluoroquinolone ( Levofloxacin 750 mg 750\text{ mg} 750 mg daily or Moxifloxacin 400 mg 400\text{ mg} 400 mg daily) Combination covers typical encapsulated bacteria and atypical pathogens. Respiratory FQs reserved for beta-lactam allergy or clinical failure due to tendinopathy, QTc, and C. difficile risks
Inpatient: Non-Severe (General Ward) IV Ceftriaxone ( 1 − 2 g 1-2\text{ g} 1 − 2 g daily) PLUS Azithromycin ( 500 mg 500\text{ mg} 500 mg daily); OR IV Levofloxacin / Moxifloxacin Standard duration is 5 days minimum ; patient must be afebrile for ≥ 48 hours \ge 48\text{ hours} ≥ 48 hours and clinically stable before discontinuing
Pediatric Acute Otitis Media (AOM)
First-Line: High-Dose Amoxicillin ( 80 − 90 mg/kg/day 80-90\text{ mg/kg/day} 80 − 90 mg/kg/day divided BID or TID) for 5-10 days.
Second-Line / Beta-Lactamase Coverage: High-Dose Amoxicillin/Clavulanate ( 90 mg/kg/day 90\text{ mg/kg/day} 90 mg/kg/day amoxicillin component with 6.4 mg/kg/day 6.4\text{ mg/kg/day} 6.4 mg/kg/day clavulanate in a 14:1 ratio formulation to prevent clavulanate-induced diarrhea). Indicated if amoxicillin used within 30 days, concurrent purulent conjunctivitis, or clinical failure after 48-72 hours.
Group A Streptococcal Pharyngitis ( S. pyogenes )
First-Line: Penicillin V ( 300 mg 300\text{ mg} 300 mg PO TID in children, 600 mg 600\text{ mg} 600 mg BID in adults) or Amoxicillin ( 50 mg/kg/day 50\text{ mg/kg/day} 50 mg/kg/day once daily or divided BID) for a full 10-day course to prevent acute rheumatic fever.
Urinary Tract Infections (UTIs)
Escherichia coli accounts for > 75 − 85 % > 75-85\% > 75 − 85% of community UTIs, followed by Klebsiella pneumoniae , Proteus mirabilis , and Staphylococcus saprophyticus .
Uncomplicated Cystitis in Non-Pregnant Females
Nitrofurantoin Monohydrate / Macrocrystals ( MacroBID ): 100 mg 100\text{ mg} 100 mg PO BID with food for 5 days . Efficacy remains high with minimal resistance. Contraindication: Avoid if eGFR < 30 mL/min \text{eGFR} < 30\text{ mL/min} eGFR < 30 mL/min (inadequate urinary concentrations and risk of peripheral neuropathy/pulmonary toxicity). Not indicated for pyelonephritis due to negligible tissue penetration.
Fosfomycin Tromethamine: 3 g 3\text{ g} 3 g PO single-dose dissolved in cold water. Inactivates MurA (peptidoglycan synthesis).
Trimethoprim-Sulfamethoxazole (TMP-SMX DS): 160 / 800 mg 160/800\text{ mg} 160/800 mg PO BID for 3 days . Use only if local E. coli resistance is < 20 % < 20\% < 20% or guided by susceptibility.
Fluoroquinolones (Ciprofloxacin, Levofloxacin): Do not use for uncomplicated cystitis due to safety warnings (aortic aneurysm, tendinopathy, dysglycemia, peripheral neuropathy) and stewardship principles.
Complicated UTI and Acute Pyelonephritis
Outpatient Pyelonephritis: Oral Ciprofloxacin ( 500 mg 500\text{ mg} 500 mg PO BID x 7 days) or Levofloxacin ( 750 mg 750\text{ mg} 750 mg PO daily x 5 days) if local FQ resistance < 10 % < 10\% < 10% ; otherwise, administer initial IV dose of Ceftriaxone ( 1 g 1\text{ g} 1 g ) prior to oral therapy. Total duration 7 − 14 7-14 7 − 14 days.
Asymptomatic Bacteriuria (ASB)
ASB is defined as ≥ 10 5 CFU/mL \ge 10^5\text{ CFU/mL} ≥ 1 0 5 CFU/mL of bacteria in urine without urinary symptoms. Treat ONLY in:
Pregnant individuals: (increases risk of pyelonephritis, low birth weight, preterm delivery). Screen at 12-16 weeks; treat with cephalexin, nitrofurantoin (avoid in 1st trimester and near term at 36-42 weeks due to neonatal hemolytic anemia), or amoxicillin/clavulanate for 3-7 days.
Patients undergoing invasive urological procedures with suspected mucosal trauma. Do NOT screen or treat ASB in catheterized patients, elderly nursing home residents, non-pregnant premenopausal women, or diabetic patients.
Skin and Soft Tissue Infections (SSTIs)
Non-Purulent Cellulitis: (Spreading erythema, warmth, edema; predominantly Streptococcus pyogenes and methicillin-sensitive Staphylococcus aureus [MSSA]). Treat with Cephalexin ( 500 mg 500\text{ mg} 500 mg PO QID), Cefadroxil ( 500 mg 500\text{ mg} 500 mg PO BID), or Cloxacillin ( 500 mg 500\text{ mg} 500 mg PO QID) for 5-7 days.
Purulent Cellulitis / Cutaneous Abscess: (Predominantly community-acquired MRSA [ CA-MRSA ]). Incision and drainage (I&D) is the primary definitive treatment. If systemic signs or extensive surrounding cellulitis present, add oral antibiotics with MRSA activity: TMP-SMX ( 1 − 2 DS tabs 1-2\text{ DS tabs} 1 − 2 DS tabs PO BID), Doxycycline ( 100 mg 100\text{ mg} 100 mg PO BID), or Clindamycin ( 300 − 450 mg 300-450\text{ mg} 300 − 450 mg PO TID) for 5-10 days.
Severe Inpatient MRSA Infections: IV Vancomycin (target AUC/MIC ratio 400 − 600 400-600 400 − 600 ), Daptomycin ( 6 − 10 mg/kg 6-10\text{ mg/kg} 6 − 10 mg/kg IV daily; inactivated by pulmonary surfactant, do not use in pneumonia ), or Linezolid ( 600 mg 600\text{ mg} 600 mg PO/IV BID; weak MAO inhibitor, monitor for serotonin syndrome and myelosuppression with prolonged use > 14 days > 14\text{ days} > 14 days ).
Sexually Transmitted Infections (Canadian Public Health Guidelines)
Infection Etiologic Agent First-Line Therapy Alternative / Special Considerations
Chlamydia Chlamydia trachomatis Doxycycline ( 100 mg 100\text{ mg} 100 mg PO BID x 7 days) Azithromycin ( 1 g 1\text{ g} 1 g PO single dose) preferred in pregnancy or confirmed non-compliance
Gonorrhea Neisseria gonorrhoeae Ceftriaxone ( 250 − 500 mg 250-500\text{ mg} 250 − 500 mg IM single dose) Add Doxycycline ( 100 mg 100\text{ mg} 100 mg BID x 7d) if chlamydia not excluded. If ceftriaxone allergy: Gentamicin 240 mg 240\text{ mg} 240 mg IM + Azithromycin 2 g 2\text{ g} 2 g PO
Syphilis (Primary, Secondary, Early Latent < 1 yr < 1\text{ yr} < 1 yr ) Treponema pallidum Benzathine Penicillin G ( 2.4 million units 2.4\text{ million units} 2.4 million units IM single dose) Doxycycline 100 mg 100\text{ mg} 100 mg PO BID x 14 days if severe penicillin allergy (non-pregnant)
Syphilis (Late Latent > 1 yr > 1\text{ yr} > 1 yr , Unknown) Treponema pallidum Benzathine Penicillin G ( 2.4 million units 2.4\text{ million units} 2.4 million units IM weekly x 3 doses) Pregnant patients with syphilis and penicillin allergy must undergo penicillin desensitization
Neurosyphilis Treponema pallidum Aqueous Crystalline Penicillin G ( 18 − 24 million units/day 18-24\text{ million units/day} 18 − 24 million units/day IV x 10-14 days) IV continuous or divided q4h
Trichomoniasis Trichomonas vaginalis Metronidazole ( 500 mg 500\text{ mg} 500 mg PO BID x 7 days) Abstain from alcohol during and for 24-48 hours after treatment (disulfiram-like reaction)
Clostridioides difficile Infection (CDI)
C. difficile is a toxin-producing, spore-forming anaerobic bacterium triggered by broad-spectrum antibiotic exposure (clindamycin, fluoroquinolones, cephalosporins, carbapenems).
Initial Episode (Non-Severe or Severe):
Oral Vancomycin: 125 mg 125\text{ mg} 125 mg PO QID for 10 days .
Oral Fidaxomicin: 200 mg 200\text{ mg} 200 mg PO BID for 10 days (narrow-spectrum, lower recurrence rates, preserves gut microbiome).
Practice Change: Oral metronidazole is no longer recommended for initial CDI due to inferior clinical cure rates.
Fulminant CDI (Hypotension, Shock, Ileus, Toxic Megacolon):
High-dose Oral Vancomycin ( 500 mg 500\text{ mg} 500 mg PO/NG tube QID) PLUS IV Metronidazole ( 500 mg 500\text{ mg} 500 mg IV q8h) PLUS Vancomycin retention enema if ileus present.
Recurrent CDI:
First Recurrence: Fidaxomicin 200 mg 200\text{ mg} 200 mg BID x 10d (if vancomycin used initially) or tapered/pulsed oral vancomycin regimen.
Multiple Recurrences ( ≥ 2 \ge 2 ≥ 2 recurrences): Fecal Microbiota Transplantation (FMT) or Bezlotoxumab (monoclonal antibody targeting C. difficile Toxin B).
Beta-Lactam Allergy Assessment and Cross-Reactivity
Up to 10 % 10\% 10% of patients report a penicillin allergy, but > 90 − 95 % > 90-95\% > 90 − 95% are found to be tolerant upon formal evaluation. +-------------------------------------------------------------------------+
- | BETA-LACTAM ALLERGY EVALUATION |
- +-------------------------------------------------------------------------+
- | |
- | Type I IgE-Mediated (Immediate < 1 hr): |
- | - Anaphylaxis, bronchospasm, laryngeal edema, acute urticaria/hives |
- | - Mechanism: Specific IgE against core beta-lactam ring / side chains |
- | |
- | Non-IgE / T-Cell Mediated (Delayed > 72 hrs): |
- | - Mild, flat, non-pruritic maculopapular exanthem (low risk) |
- | - Severe Cutaneous Adverse Reactions (SCARs): SJS, TEN, DRESS, AGEP |
- | --> ABSOLUTE CONTRAINDICATION to re-exposure with ANY beta-lactam |
- | |
- | Cross-Reactivity Truths: |
- | - Cross-reactivity between penicillins and 3rd/4th gen cephalosporins |
- | (ceftriaxone, cefepime) or carbapenems (meropenem) is < 1-2%. |
- | - Cross-reactivity is driven by IDENTICAL R1 SIDE CHAINS (e.g., |
- | Amoxicillin shares identical side chain with Ampicillin, Cefadroxil, |
- | and Cefprozil; Ampicillin shares side chain with Cephalexin). |
- +-------------------------------------------------------------------------+